Effect of a long-acting somatostatin derivative sms 201-995 (sandostatin) on glucose homeostasis in type i diabetes mellitus

Hormone Research in Paediatrics

Volumn 29, Issue 2-3, 1988, Pages 92-94

  Navascues, I ^a   Gil, J ^a   Pascau, C ^a   Senen D ^a   Del Pozo, E ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Sandoz Pharma Ltd   (Switzerland)

Author keywords

Counterregulation; Dawn phenomenon; Diabetes control; Somatostatin

Indexed keywords

OCTREOTIDE;

CLINICAL ARTICLE; CONTROLLED STUDY; COUNTERREGULATION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MORNING HYPERGLYCEMIA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

BLOOD GLUCOSE; CIRCADIAN RHYTHM; DIABETES MELLITUS, INSULIN-DEPENDENT; GROWTH HORMONE; HOMEOSTASIS; HUMAN; HYPOGLYCEMIC AGENTS; INSULIN INFUSION SYSTEMS; OCTREOTIDE; SOMATOSTATIN;

EID: 0023785136     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000180977     Document Type: Article

References (6)

1. Gottesmann, I.S.; Mandarino, I.J.; Gcrich, J.E.: Somatostatin: its role in health and disease. Spec. Top. Endocrinol. Metab. 4; 177–243 (1982).
2. Bauer, W.; Briner, U.; Doepfner, W.; Hall, R.; Huguenin, R.; Marbach, P.; Pctchcr, T.J.; Pless, J.: SMS 201–995: a very potent and selective octapcptide analogue of somatostatin with prolonged action. Life Sei. 31: 1133–1141 (1982).
3. Pozo, E. del Kutz, K.: Pharmacological properties and effect on glucose homeostasis of a somatostatin derivative (SMS 201 -995): studies in humans; in Liidecke, Tolis, Growth factors and acromegaly, pp. 207–214 (Raven Press, New York, 1987).
4. Pozo, E. del Lamberts, S.W.J.; Sieber, C; Gomez-Pan, A.: Effect of a long-acting somatostatin analog (SMS 201–995) on glucose homeostasis in type I diabetes and in acromegaly: in Reichlin, Somatostatin, basic and clinical status, pp. 293–302 (Plenum Press, New York. 1987).
5. Serrano-Rios, M.; Navascues, I.; Saban, J.: Ordonez, A.; Sevilla, F.; del Pozo, E.: Somatostatin analog SMS 201–995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas. J. clin. Endocr. Metab. 53: 675–681(1987).
6. Campbell, P.: Bolli, G.; Cryer, P.; Gerich, J.: Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. N. Engl. J. Med. 312: 1473–1479 (1985).